Transce3nd LLC Makes New $96,000 Investment in Hologic, Inc. (NASDAQ:HOLX)

Transce3nd LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,333 shares of the medical equipment provider’s stock, valued at approximately $96,000.

Several other hedge funds have also made changes to their positions in HOLX. General Partner Inc. bought a new position in Hologic during the fourth quarter valued at about $26,000. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co lifted its position in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 400 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock opened at $56.94 on Tuesday. Hologic, Inc. has a 1 year low of $55.89 and a 1 year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm’s 50 day moving average is $61.45 and its 200-day moving average is $70.54. The firm has a market capitalization of $12.78 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HOLX. Evercore ISI dropped their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.